基于蛋白质的四价脑膜炎球菌疫苗对感染的有效性：加拿大的越来越多的证据及公共卫生影响
Effectiveness of the four-component protein-based meningococcal vaccine against infections: Mounting evidence and public health implications for Canada.
作者信息
De Wals Philippe, Bui Yen-Giang, Desjardins Michaël
机构信息
Département de médecine sociale et préventive, Université Laval, Québec City, QC.
Institut national de santé publique du Québec, Québec City, QC.
出版信息
Can Commun Dis Rep. 2025 Aug 28;51(8):312-318. doi: 10.14745/ccdr.v51i08a04. eCollection 2025 Aug.
BACKGROUND
In Canada, the burden of gonorrhea has been increasing steadily over the last decade with emerging multi-drug-resistant strains. There is a high genomic similarity between and .
METHODS
Review of published studies and on-going trials with the four-component meningococcal serogroup B vaccine (4CMenB-Bexsero®).
RESULTS
Observational studies have shown protection against gonorrhea infection ranging from 35% to 59% for up to three years after the administration of 4CMenB. Several randomized clinical trials are also under way. Results from the DOXYVAC trial have been published but the sample size was too small to exclude a protective effect in the 30%-50% range. Recommendations on the use of 4CMenB for individuals at high risk of gonorrhea infection have been issued in the United Kingdom and New York state based on results of observational studies.
CONCLUSION
If results of observational studies are confirmed by randomized trials with an acceptable cost-effectiveness profile in the Canadian context, a targeted immunization program using 4CMenB could be implemented.
背景
在加拿大，过去十年间淋病负担随着新出现的多重耐药菌株而稳步增加。[此处原文缺失部分内容]与[此处原文缺失部分内容]之间存在高度的基因组相似性。
方法
回顾已发表的研究以及正在进行的关于四价B群脑膜炎球菌疫苗（4CMenB - Bexsero®）的试验。
结果
观察性研究表明，接种4CMenB后长达三年对淋病感染的保护率在35%至59%之间。多项随机临床试验也在进行中。DOXYVAC试验的结果已发表，但样本量过小，无法排除30%至50%范围内的保护作用。基于观察性研究结果，英国和纽约州已发布了关于4CMenB用于淋病感染高危个体的使用建议。
结论
如果观察性研究结果在加拿大背景下通过具有可接受成本效益的随机试验得到证实，那么可以实施使用4CMenB的针对性免疫计划。
Zotero 插件